# OnCo record hta (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/hta/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "hta" ;
  schema:name "Health technology assessment (HTA), reimbursement and QALYs"@en ;
  schema:alternateName "HTA"@en, "health technology assessment"@en, "reimbursement"@en, "reimbursed"@en, "reimbursement decision"@en, "coverage decision"@en, "payer"@en, "payers"@en, "cost-effectiveness"@en, "cost effectiveness"@en, "cost-effective"@en, "QALY"@en, "QALYs"@en, "quality-adjusted life year"@en, "incremental cost-effectiveness ratio"@en, "willingness-to-pay threshold"@en, "value-based pricing"@en, "managed access"@en, "Cancer Drugs Fund"@en, "technology appraisal"@en, "G-BA"@en, "AMNOG"@en, "HAS"@en, "PBAC"@en, "CADTH"@en, "value assessment"@en, "coverage decisions"@en, "technology appraisals"@en ;
  schema:description "Approval says a drug works; reimbursement says who will pay. Health technology assessment bodies (NICE, G-BA, PBAC) judge whether the benefit is worth the price, often per quality-adjusted life year, and can delay access for years after approval."@en ;
  schema:url <https://onco.cc/terms/hta/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Health_technology_assessment> ;
  schema:citation <https://en.wikipedia.org/wiki/Health_technology_assessment> ;
  onco:related <https://onco.cc/terms/qol-pro/>, <https://onco.cc/terms/financial-toxicity/>, <https://onco.cc/terms/regulatory-agencies/>, <https://onco.cc/terms/real-world-evidence/>, <https://onco.cc/terms/eu-hta-regulation/>, <https://onco.cc/terms/nice-methods/>, <https://onco.cc/terms/cancer-drugs-fund/>, <https://onco.cc/terms/innovative-medicines-fund/>, <https://onco.cc/terms/amnog/>, <https://onco.cc/terms/inflation-reduction-act/>, <https://onco.cc/terms/medicare-ced/>, <https://onco.cc/terms/france-early-access/>, <https://onco.cc/terms/china-vbp-nrdl/>, <https://onco.cc/terms/state-biomarker-testing-laws/> ;
  onco:sections <https://onco.cc/fronts/drug-discovery/> ;
  onco:technologies <https://onco.cc/collections/nice-guidance/>, <https://onco.cc/terms/icer-value-assessment/>, <https://onco.cc/terms/drug-price-transparency/> .